Abstract
Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An altered expression of the multidrug resistance 1 may represent an additional prognostic marker. Aim of our study was to evaluate two MDR-1 gene polymorphisms: G2677T polymorphism in exon 21 and C3435T polymorphism in exon 26, to evidence if polymorphisms influence the risk of development of B-CLL and whether genomic polymorphisms provide prognostic information on the clinical progression of the disease. A total of 125 patients with B-CLL and 125 healthy subjects were enrolled in this study. The mutant homozygous 2677 TT genotype was found to be associated with the occurrence of B-CLL and higher T allele frequency in patients with B-CLL when compared with controls was observed (P = 0.009). When comparing the prognostic patients’ characteristics, patients with 2677 GT genotype were statistically linked to the unmutated IgVH genes (r = 0.209, P = 0.01). Moreover, the same genotype was correlated with lymphocyte number (r = 0.269, P = 0.02). Finally for the 2677GT polymorphism, the heterozygous status was associated with higher hemoglobin levels (r = 0.247, P = 0.005). As far the C3435T MDR1 polymorphism, we were not able to identify any significant correlation with IgVH gene status or other variables. In conclusion, MDR1 gene polymorphism could be a factor predisposing to LLC. Moreover, our findings support the possibility of considering these genomic polymorphisms as prognostic markers in patients with B-CLL.
Similar content being viewed by others
References
Wulf G. Multidrug resistance phenotype in patients with chronic lymphocytic leukemia as detected by immunofluorescence (FACS) and northen blot analysis. Leuk Res. 1994;18:475–84.
Iyer L, Raain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer. 1998;34:1493–9.
Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev. 2002;54:1295–310.
Jamroziak K, Robak T. Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology. 2004;9:91–105.
Marzolini C, Paulus E, Buclin T, Kim RB. Polimorphorsms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13–33.
Kim RB, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189–99.
Kim RB. Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in the novo acute myeloid leukemia. Int J Cancer. 2005;118:2195–201.
Hoffmeyer S, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473–8.
Hitzl M, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics. 2001;11:293–8.
Schaich M, Sourcek S, Thiede C, Ehninger G, Ilmer T. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol. 2005;128:324–32.
Kim DH, et al. Multidrug resistance as a potential prognostic indicator in acute myeoid leukemia with normal karyotypes. Acta Haematol. 2005;114:78–83.
Monzo M, et al. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood. 2006;107:4871–9.
Stanulla M, et al. GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int J Hematol. 2005;81:39–44.
Van der Holt B, et al. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther. 2006;80:427–39.
Buda G, et al. MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol. 2007;137:454–6.
Maggini V, et al. MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet Genomics. 2008;18:383–9.
Kim DH, Park JY, Sohn SK, Lee NY, Lee KB. The association between multidrug resistance-1 gene polymorphisms and outcomes of allogenic HLA-identical stem cell transplantation. Haematologica. 2006;91:848–51.
Dulucq S, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2008;112:2024–7.
Zheng H, et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in paediatric heart transplant patients. Him Immunol. 2002;63:765–70.
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–54.
Ni LN et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol. 2010 Mar 4. [Epub ahead of print].
Turgut S, Yaren A, Kursunluoglu R, Turgut G. MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res. 2007;38:539–44.
Tatari F. Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population. DNA Cell Biol. 2009;28:259–63.
Goreva OB, Grishanova AY, Mukhin OV, Domnikova NP, Lyakhovich VV. Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T polymorphisms. Bull Exp Biol Med. 2003;136:183–5.
Jamroziak K, et al. Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res. 2009;33:332–5.
Rochlitz CF, et al. PCR-determined expression of the MDR1 gene in chronic lymphocytic leukemia. Ann Hematol. 1992;65:241–6.
Guillaume N, et al. Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2007;48:1468–9.
Rund D, Azar I, Shperling O. A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease. Adv Exp Med Biol. 1999;457:71–5.
Jamroziak K, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibly and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol. 2004;72:314–21.
Hattori H, et al. Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukemia. Leuk Res. 2007;31:1633–40.
Krajinovic M, Labuda D, Richier C, Karimi S, Sinnett D. Susceptibility to childhood lymphoblastic leukemia: influence of CYP1a1, CYP2D6, GSTM1 and GSTT1 genetic polymorphism. Blood. 1999;93:496–1501.
Potocnik U, Ravnik-Glavac M, Glavac D. Functional MDR1 polymorphisms (G2677T and C3435T) and TCF4 mutations in colorectal tumors with high microsatellite instability. Cell Mol Biol Lett. 2002;7:92–5.
Golapud S, Gupta S. Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival. J Clin Immunol. 2001;21:420–30.
Mattews C, et al. MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVh genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia. Leuk Lymph. 2006;47:2308–13.
Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Kurzawski M, Gawronska-Szklarz B. Involvement of C3435T and G 2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. Eur J Pharmacol. 2005;528:27–36.
Li JP, Zhang CL, Han ZC. Abnormal immunity and stem/progenitor cells in acquired aplastic anemia. Crit Rev Oncol Hematol. 2009. Epub ahead of print.
Tsopra OA, Ziros PG, Lagadinou ED, Symeonidis A, Kouraklis-Symeonidis A, Thanopoulou E, Angelopoulou MK, Vassilakopoulos TP, Pangalis GA, Zoumbos NC. Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factor-alpha. Acta Haematol. 2009;121:187–95.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Penna, G., Allegra, A., Alonci, A. et al. MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis. Med Oncol 28, 1549–1554 (2011). https://doi.org/10.1007/s12032-010-9561-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-010-9561-9